Search Clinical Trials in the EU

Duration

Visits

Confirmation phase (III)

Intake methods

Benefits

Drugs

Locations

Clinical Specialty

581-600 of 1,307 trials

Heart Failure: Stopping Beta-Blockers

We are studying whether discontinuing beta-blockers is as safe for patients with improved heart function as continuing the medication. This trial aims to understand the effects on heart failure relapse and overall heart health.

Heart Failure>2 yearsConfirmation phase (III)Investigational Medicines Cost Reimbursement Partially RemoteCardiologyInternal Medicine

Ulcerative Colitis and Crohn’s Disease: Vedolizumab for Kids

We are studying the long-term safety of vedolizumab in children with ulcerative colitis or Crohn’s disease. The trial also looks at how this treatment affects their quality of life and related health events.

Ulcerative ColitisCrohn's Disease1-2 yearsConfirmation phase (III)6-10 visits Post-Trial Drug Access No Placebo Standard Medicines Cost ReimbursementGastroenterologyPediatrics

Refractory Focal Onset Epilepsy: BHV-7000 Study

We are testing a new medication, BHV-7000, to see if it can help reduce seizures in adults with refractory focal onset epilepsy. The study compares its effects to a placebo to evaluate safety and effectiveness.

Focal Epilepsy3-6 monthsEfficacy phase (II)Confirmation phase (III)≤5 visits Post-Trial Drug Access Investigational Medicines Cost ReimbursementNeurology

BHV-7000 for Idiopathic Generalized Epilepsy

We are studying a new treatment for people with idiopathic generalized epilepsy who have generalized tonic-clonic seizures. The trial will compare its effects to a placebo to see if it helps reduce seizure frequency and is safe to use.

Idiopathic Generalized Epilepsy6-12 monthsEfficacy phase (II)Confirmation phase (III)16-20 visits Post-Trial Drug Access Investigational Medicines Cost ReimbursementNeurology

Familial Chylomicronemia Syndrome: AKCEA-APOCIII-LRX Study

We are testing a new subcutaneous treatment for patients with Familial Chylomicronemia Syndrome who have previously used volanesorsen. The study aims to evaluate its safety and how well it is tolerated.

Familial Chylomicronemia Syndrome>2 yearsConfirmation phase (III)>20 visits Post-Trial Drug Access No Placebo Investigational Medicines Partially RemoteEndocrinologyHematology

Perennial Allergic Rhinitis: Lebrikizumab Study

We are testing a new medication, lebrikizumab, to see if it helps adults with perennial allergic rhinitis experience fewer nasal symptoms. This study compares its effects to a placebo treatment.

Perennial Allergic RhinitisConfirmation phase (III)6-10 visits Standard Medicines Cost Reimbursement Partially RemoteAllergologyOtolaryngologyPulmonology

Epidermolysis Bullosa Simplex: Diacerein 1% Ointment

We are studying a new ointment for people with generalized Epidermolysis Bullosa Simplex to see if it helps improve skin condition and reduce symptoms. The trial includes both adults and children aged 6 months and older.

Epidermolysis Bullosa Simplex1-2 yearsEfficacy phase (II)Confirmation phase (III)Post-Trial Drug Access Investigational Medicines Cost Reimbursement Partially RemoteDermatology

Knee Osteoarthritis: Genicular Arteries Embolization Study

We are investigating whether a new procedure can help reduce knee pain in people with symptomatic knee osteoarthritis. Participants will compare this treatment to a sham procedure to assess its effectiveness.

Knee Osteoarthritis>2 yearsConfirmation phase (III)6-10 visits Standard Medicines Partially RemoteInternal MedicineOrthopedics and Traumatology

Juvenile Idiopathic Arthritis: Bimekizumab Study

We are studying the safety and how bimekizumab moves in the body for children aged 2 to under 18 with certain types of juvenile idiopathic arthritis. This research aims to help improve treatment options for these young patients.

Juvenile Arthritis and Related Conditions6-12 monthsConfirmation phase (III)Post-Trial Drug Access No Placebo Standard Medicines Partially RemotePediatricsRheumatology

Metastatic Colorectal Cancer: Tinzaparin for Blood Clot Prevention

We are studying whether tinzaparin can help prevent blood clots in patients with metastatic colorectal cancer starting their first line of treatment. This may help reduce the risk of complications related to blood clots.

Metastatic Colorectal CancerThromboembolic Event>2 yearsConfirmation phase (III)No Placebo Standard MedicinesCardiologyOncology

Staccato Alprazolam for Prolonged Seizures in Ages 12 and Up

We are studying the safety of Staccato Alprazolam for treating long seizures in children and adults. This trial will help us learn how well it works and its effects on lung health over time.

Prolonged Seizure>2 yearsConfirmation phase (III)11-15 visits Post-Trial Drug Access Investigational Medicines Cost Reimbursement Partially RemoteNeurology

Heart Failure: Finerenone and SGLT2 Inhibitor Study

We are investigating whether a combination of finerenone and an SGLT2 inhibitor can improve health outcomes for hospitalized heart failure patients. This study aims to see if this approach leads to better symptom relief and fewer hospital visits.

Heart Failure1-2 yearsConfirmation phase (III)No Placebo Standard Medicines Cost Reimbursement Partially RemoteCardiologyInternal Medicine

Heart Failure: Finerenone Study

We are testing the medication finerenone for patients with heart failure who cannot tolerate standard treatments. The study aims to see if it is safe and effective for these individuals.

Heart Failure>2 yearsConfirmation phase (III)≤5 visits Investigational Medicines Cost Reimbursement Partially RemoteCardiologyInternal Medicine

Advanced Lung Cancer: Adagrasib and Pembrolizumab Study

We are testing a new treatment combining adagrasib with pembrolizumab for patients with advanced non-small cell lung cancer with a KRAS G12C mutation. The goal is to see if this combination works better than pembrolizumab alone.

Advanced Non-Small Cell Lung CancerEfficacy phase (II)Confirmation phase (III)No Placebo Standard Medicines Cost Reimbursement Partially RemoteOncologyPulmonology

Childhood Renal Tumors: Comparing Chemotherapy Treatments

We are studying two chemotherapy combinations for children with stage IV renal tumors to see which one works better and has fewer side effects. This research aims to improve treatment outcomes for young patients.

Nephroblastoma6-12 monthsConfirmation phase (III)No Placebo Standard MedicinesNephrologyOncologyPediatrics

Hidradenitis Suppurativa: Secukinumab Treatment Study

We are investigating the long-term effects of secukinumab on people with moderate to severe hidradenitis suppurativa. This study will help us understand its safety and effectiveness compared to a placebo.

Hidradenitis Suppurativa>2 yearsConfirmation phase (III)16-20 visits Post-Trial Drug Access Investigational Medicines Cost Reimbursement Partially RemoteAllergologyDermatology

HER2-Positive Breast Cancer: Zanidatamab vs. Trastuzumab

We are studying whether zanidatamab combined with chemotherapy is more effective and safer than trastuzumab with chemotherapy for patients with metastatic HER2-positive breast cancer who have not responded to previous treatments.

Metastatic HER2-positive Breast Cancer3-6 monthsConfirmation phase (III)No Placebo Investigational Medicines Cost ReimbursementOncology

Pancreatic Cancer: Antiplatelet Therapy Study

We are investigating if adding an antiplatelet medication to standard care can help prevent blood clots in patients with pancreatic cancer. We also want to see if it may improve survival rates.

Pancreatic Ductal Cancer6-12 monthsConfirmation phase (III)6-10 visits No Placebo Standard Medicines Partially RemoteCardiologyOncology

Vedolizumab for Children with Moderate to Severe Crohn's Disease

We are studying how well different doses of vedolizumab help children and teenagers with Crohn's disease maintain their health. The goal is to see if it can keep symptoms under control and improve their overall well-being.

Crohn's Disease1-2 yearsConfirmation phase (III)Post-Trial Drug Access No Placebo Standard Medicines Cost ReimbursementGastroenterologyPediatrics

Ulcerative Colitis and Crohn's Disease: Vedolizumab IV in Kids

We are studying the long-term safety of vedolizumab IV in children and teenagers with ulcerative colitis or Crohn's disease. This research aims to understand its effects on health and quality of life.

Active Ulcerative Colitis or Crohn's Disease>2 yearsConfirmation phase (III)>20 visits Post-Trial Drug Access No Placebo Standard Medicines Cost ReimbursementGastroenterology

Search Clinical Trials in the European Union